An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Auton. de Buenos Aires, C1181ACL, Argentina
Bruxelles - Brussel, 1070, Belgium
Bruxelles - Brussel, 1090, Belgium
Bruxelles - Brussel, 1200, Belgium
Montreal, Quebec, H4A 3J1, Canada
Bad Friedrichshall, Baden-Wurttemberg 74177, Germany
Karlsbad, Baden-Wurttemberg 76307, Germany
Asahikwa, Hokkaido 078-8510, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Itabashi-ku, Tokyo 173-0015, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Meguro-ku, Tokyo 152-8902, Japan
Minato-ku, Tokyo 108-8329, Japan
Suginami-ku, Tokyo 166-0001, Japan
Jung-gu Daejeon, 35015, South Korea